Alector Reports Baseline Characteristics for Phase 3 Latozinemab Trial for Frontotemporal Dementia

MT Newswires Live09-19

Alector (ALEC) said Thursday that the baseline characteristics of its phase 3 clinical trial evaluating latozinemab "suggest a representative study population" which "enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation."

Alector said the baseline clinical assessments show that the trial enrolled the intended population of participants with frontotemporal dementia. It added that this will allow the company to test its hypothesis that the drug candidate "may slow disease progression."

The biotech firm said it is developing the drug candidate with British pharmaceutical company GSK (GSK). Shares of Alector were up 3.2% in recent premarket activity.

Price: 5.82, Change: +0.18, Percent Change: +3.19

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468457105?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-19 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468457105","market":"fut","top_or_hot":-1,"title":"Alector Reports Baseline Characteristics for Phase 3 Latozinemab Trial for Frontotemporal Dementia","media":"MT Newswires Live","content":"<html><body><p> Alector (ALEC) said Thursday that the baseline characteristics of its phase 3 clinical trial evaluating latozinemab \"suggest a representative study population\" which \"enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation.\"</p><p>Alector said the baseline clinical assessments show that the trial enrolled the intended population of participants with frontotemporal dementia. It added that this will allow the company to test its hypothesis that the drug candidate \"may slow disease progression.\"</p><p>The biotech firm said it is developing the drug candidate with British pharmaceutical company GSK (GSK). Shares of Alector were up 3.2% in recent premarket activity.</p><p>Price: 5.82, Change: +0.18, Percent Change: +3.19</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alector Reports Baseline Characteristics for Phase 3 Latozinemab Trial for Frontotemporal Dementia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlector Reports Baseline Characteristics for Phase 3 Latozinemab Trial for Frontotemporal Dementia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-19 21:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alector (ALEC) said Thursday that the baseline characteristics of its phase 3 clinical trial evaluating latozinemab \"suggest a representative study population\" which \"enables testing of the effects of...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2468457105","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468457105","pubTimestamp":1726751147,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Alector  said Thursday that the baseline characteristics of its phase 3 clinical trial evaluating latozinemab \"suggest a representative study population\" which \"enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation.\"Alector said the baseline clinical assessments show that the trial enrolled the intended population of participants with frontotemporal dementia. It added that this will allow the company to test its hypothesis that the drug candidate \"may slow disease progression.\"The biotech firm said it is developing the drug candidate with British pharmaceutical company GSK . Shares of Alector were up 3.2% in recent premarket activity.Price: 5.82, Change: +0.18, Percent Change: +3.19","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4007":"制药","BK4532":"文艺复兴科技持仓","GSK.UK":"葛兰素史克","GSK":"葛兰素史克","ALEC":"Alector Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"Alector报告额颞叶痴呆3期Latozinemab试验的基线特征","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALEC":0.9,"GSK":0.9,"GSK.UK":0.6},"content_text":"Alector (ALEC) said Thursday that the baseline characteristics of its phase 3 clinical trial evaluating latozinemab \"suggest a representative study population\" which \"enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation.\"Alector said the baseline clinical assessments show that the trial enrolled the intended population of participants with frontotemporal dementia. It added that this will allow the company to test its hypothesis that the drug candidate \"may slow disease progression.\"The biotech firm said it is developing the drug candidate with British pharmaceutical company GSK (GSK). Shares of Alector were up 3.2% in recent premarket activity.Price: 5.82, Change: +0.18, Percent Change: +3.19","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468457105"}